Figure 1.
Effect of relebactam on MIC distribution of imipenem against: (A) P. aeruginosa isolates (n = 1886); (B) imipenem-non-susceptible P. aeruginosa (n = 835); (C) MDR P. aeruginosa isolates (n = 835). Dashed line represents the FDA identified susceptibility breakpoint of imipenem/relebactam of ≤ 2 mg/mL for P. aeruginosa.
Abbreviations: MIC, minimum inhibitory concentrations; MDR, multidrug resistance.